Skip to main content
QuestionsResearchTagsGuidelinesLeaderboard
tachyDx Research Portal

Research tagged [pulmonology]

Every paper is generated from a real clinical discussion on tachyDx, peer-reviewed by verified physicians, and published with a unique TDX identifier. All contributors are credited.

DOIs registered viaCrossref
Published26Under ReviewFlagged
Clear filters

5 papers

TDX-2026-00023

Antifibrotic Therapy in Progressive Rheumatoid Arthritis-Associated Interstitial Lung Disease with a Usual Interstitial Pneumonia Pattern: Expert Perspectives on Treatment Selection and Monitoring

Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) represents a significant cause of morbidity and mortality in patients with rheumatoid arthritis, particularly when presenting with a usual interstitial pneumonia (UIP) pattern and demonstrating progressive fibrosing characteristics. This paper synthesizes expert opinions from a clinical Q&A discussion regarding the management of a 58-year-old female with progressive RA-ILD (UIP pattern) despite immunosuppression. The primary clinical dilemma revolves around the selection between nintedanib and pirfenidone, the continuation of background immunosuppression, and optimal monitoring strategies. Expert consensus favored nintedanib as a first-line antifibrotic due to robust evidence from the INBUILD trial, particularly within the UIP subgroup. However, an alternative perspective highlighted pirfenidone's potential anti-inflammatory properties and institutional experience in connective tissue disease-associated ILD. Both experts strongly advocated for the continuation of mycophenolate, citing the potential for subclinical inflammation and the risks of disease flare or acceleration upon withdrawal. A comprehensive monitoring protocol incorporating FVC, 6-minute walk distance, patient-reported outcomes, and advanced techniques like home spirometry was recommended. This synthesis underscores the complexities of managing progressive RA-ILD, emphasizing evidence-based antifibrotic selection, judicious immunosuppression, and multi-modal monitoring to optimize patient outcomes.

A physician-only Q&A platform where verified medical doctors share clinical knowledge, debate evidence, and build the knowledge base the world needs.

Powered by

Platform

  • Questions
  • Research
  • Tags
  • Guidelines
  • Leaderboard
  • Report a Bug

Ecosystem

  • Teams
  • Sponsors
  • Hiring
  • Publishing
  • CME
  • Data

Company

  • About
  • Support
  • Privacy Policy
  • Terms of Service
  • Contact

© 2026 Aethryva Deeptech Pvt Ltd. All rights reserved.

Crossref Member
2 contributors 58 votes 9 Apr 2026

TDX-2026-00019

Management of Right Ventricular Dysfunction and Weaning Protocols for Veno-Venous Extracorporeal Membrane Oxygenation in COVID-19 Acute Respiratory Distress Syndrome: A Clinical Consensus Initiative

Veno-venous extracorporeal membrane oxygenation (VV-ECMO) provides crucial life support for severe acute respiratory distress syndrome (ARDS), including that caused by COVID-19. Weaning from VV-ECMO presents complex challenges, particularly concerning persistent right ventricular (RV) dysfunction, which can complicate decannulation decisions. This paper synthesizes expert clinical perspectives on VV-ECMO weaning criteria, focusing on RV assessment, sweep gas trial protocols, and the utility of inhaled pulmonary vasodilators. Utilizing a community peer-review platform, two critical care physicians provided detailed protocols and insights, which were subsequently validated by 84 peer votes. Key findings indicate a pragmatic approach to RV dysfunction, where mild residual impairment may be acceptable if gas exchange and hemodynamic stability are maintained. Staged sweep gas trials, extending up to 6 hours, are advocated, with continuous monitoring of respiratory mechanics, gas exchange, and hemodynamic parameters. The use of inhaled iloprost as a bridge therapy for residual pulmonary hypertension during decannulation was also explored. This initiative highlights the variability in current clinical practice and provides a consensus-driven framework to guide VV-ECMO weaning in patients with COVID-19 ARDS and RV dysfunction, emphasizing individualized patient assessment and a multidisciplinary approach.

2 contributors 84 votes 9 Apr 2026

TDX-2026-00014

Optimizing Mechanical Ventilation in Obese Patients with Moderate Acute Respiratory Distress Syndrome: A Consensus-Based Approach to Driving Pressure, Plateau Pressure, and Adjunctive Therapies

Mechanical ventilation in patients with Acute Respiratory Distress Syndrome (ARDS) is complex, with obesity presenting unique challenges due to altered respiratory mechanics. This paper synthesizes expert clinical opinions from a specialized medical discussion forum, addressing critical questions regarding ventilator management in obese ARDS patients. The discussion centered on a 55-year-old obese female with moderate ARDS (P/F ratio 142), highlighting the interplay between plateau pressure, driving pressure, and adjunctive strategies. Experts advocate for tolerating higher plateau pressures (up to 33-35 cmH2O) in obese individuals, provided driving pressure remains below 15 cmH2O, acknowledging the significant contribution of chest wall elastance to airway pressure in this population. Driving pressure is emphasized as the primary ventilator target, aligning with evidence suggesting its superior predictive value for mortality. Early prone positioning is strongly recommended for eligible patients, particularly in obesity, due to its enhanced mechanical benefits. The routine use of esophageal balloon manometry for transpulmonary pressure measurement is endorsed, especially in obese patients, to personalize ventilation strategies. Practical considerations for safe prone positioning in obese patients are also detailed. This consensus highlights a shift towards individualized, physiology-guided ventilation, prioritizing transpulmonary and driving pressures while integrating evidence-based adjunctive therapies to mitigate ventilator-induced lung injury and improve outcomes in this challenging patient cohort.

3 contributors 67 votes 6 Apr 2026

TDX-2026-00011

Management of Incidental Part-Solid Pulmonary Nodules: A Community-Based Clinical Consensus on Fleischner 2017 Guidelines and PET-CT Utility

Background: Incidental pulmonary nodules are frequently detected on computed tomography (CT) scans performed for unrelated indications, posing a significant clinical challenge regarding their malignant potential and appropriate management. Part-solid nodules, in particular, carry a higher risk of malignancy compared to pure ground-glass or solid nodules, necessitating careful surveillance strategies. The Fleischner Society 2017 guidelines provide evidence-based recommendations for their management, yet clinical scenarios often present nuances that require expert interpretation and communication. Methods: This study synthesizes expert opinions from a peer-reviewed clinical Q&A platform (tachyDx), involving two verified physicians (a radiologist and a pulmonologist) and 43 community peer votes. A specific clinical case of a 48-year-old non-smoker with an incidental 7mm part-solid pulmonary nodule (4mm solid component) was presented to elicit consensus on guideline adherence, solid component thresholds for intervention, utility of PET-CT, and inter-specialty communication. Results: A strong consensus emerged for strict adherence to Fleischner 2017 guidelines for initial surveillance of sub-centimeter part-solid nodules with small solid components. The solid component size was identified as the primary determinant for risk stratification, with PET-CT deemed unhelpful for sub-centimeter lesions due to resolution limitations. Emphasis was placed on clear, structured communication of findings and the importance of early shared decision-making to address patient anxiety. Conclusions: The findings underscore the critical role of Fleischner 2017 guidelines in managing incidental part-solid pulmonary nodules. They highlight the limited utility of PET-CT for sub-centimeter lesions and advocate for patient-centered communication strategies, integrating clinical judgment with established guidelines.

2 contributors 43 votes 6 Apr 2026

TDX-2026-00007

Optimizing Bedaquiline-Based Regimens for Pre-Extensively Drug-Resistant Tuberculosis in HIV Co-infection: A Community Peer-Reviewed Clinical Consensus

Background: Pre-extensively drug-resistant tuberculosis (pre-XDR TB), characterized by resistance to isoniazid, rifampicin, and fluoroquinolones, presents a significant global health challenge, particularly in individuals co-infected with human immunodeficiency virus (HIV). The advent of novel anti-TB agents and shorter regimens, such as bedaquiline-pretomanid-linezolid (BPaL), offers improved outcomes but necessitates careful consideration of regimen composition, drug dosing, adverse event monitoring, and drug-drug interactions. Methods: This study synthesizes expert clinical opinion derived from a peer-reviewed clinical Q&A platform (tachyDx), involving two verified physicians and garnering 54 community peer votes. A clinical scenario involving a 34-year-old female with pre-XDR TB and HIV co-infection was presented, prompting discussion on regimen selection, linezolid management, QTc monitoring, antiretroviral therapy (ART) timing, and drug interactions. The accepted answer and additional insights were critically analyzed to establish a consensus. Results: The BPaL regimen was strongly favored for its shorter duration and high efficacy, contingent on pretomanid availability. Optimal linezolid dosing was identified as 600 mg daily for 26 weeks, with rigorous hematologic and neurologic monitoring. A comprehensive QTc monitoring protocol for bedaquiline, particularly in the context of dolutegravir (DTG) co-administration, was outlined. Continuation of existing ART was recommended, with specific guidance for ART-naïve patients. Critical drug-drug interactions, including those involving CYP3A4 inhibitors/inducers and monoamine oxidase inhibitors, were highlighted. Conclusions: This expert consensus provides practical, evidence-informed guidance for managing pre-XDR TB in HIV co-infected patients, emphasizing the BPaL regimen, meticulous adverse event monitoring, and proactive management of drug interactions. These recommendations aim to facilitate the safe and effective implementation of novel TB therapies in complex clinical settings.

2 contributors 54 votes 6 Apr 2026
Page 1 of 2Next →

Topics

Allpharmacology8critical-care7cardiology6emergency-medicine6oncology5pulmonology5nephrology4neurology4gastroenterology3immunology3hematology3surgery3infectious-disease3radiology2endocrinology2anesthesiology2hepatology2pediatrics2rheumatology2evidence-based-medicine1orthopedics1trauma1neonatology1psychiatry1internal-medicine1